Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Sales of Investments
Cash received from selling or redeeming investments.
Maze Therapeutics, Inc.NASDAQ: MAZE
Sales of Investments · Q1 FY2026 · quarter ended Mar 2026
Sales of investments outflow grows to $30M
Q1 FY2026 sales of investments was $30M, compared with $0 a year earlier. Trailing-twelve-month sales of investments was $47.5M.
Context
- Sales of investments increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly sales of investments holds near $30M or moves back toward the trailing-twelve-month quarterly average of $11.88M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 17.5M USD
- Year-over-year change
- —
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.5M | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Sales of Investments vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
- Sales of investments amounts to 237.5% of revenue for MAZE, versus a peer median of 91.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.34B USD | +87.1% | +18.2% | 132.6% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $268.7M USD | +47.4% | — | 279.1% |
| LTM Sep 2026 | $246.48M USD | -16.8% | -5.4% | 37.9% | |
| LTM Mar 2026 | $214.68M USD | +18.6% | +46.7% | 50.2% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $93.74M USD | — | — | 908.7% |
| LTM Mar 2026 | $60.46M USD | +3.3% | -0.1% | — | |
| LTM Mar 2026 | $47.5M USD | — | — | 237.5% | |
| FY2025 | €0 EUR | -100.0% | — | 0.0% | |
| Peer median (excluding MAZE) | — | +11.0% | +9.0% | 91.4% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.